The Latest Breaking News on Intellia

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy…

Investors Business Daily

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.

Investors Business Daily

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate…

From analysis to good news, read the world’s best news in one place

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing…

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent…

Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer

Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has

Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

Eight months after

Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test

Intellia successfully lowered a problematic protein in patients with a liver disease on Monday, but NTLA stock fell on a…

Investors Business Daily

Intellia Therapeutics Pops After Forging A Cancer Deal Worth Nearly $1 Billion

Intellia stock surged Tuesday after the CRISPR gene-editing company forged a cancer deal with Onk Therapeutics worth nearly $1 billion.

Investors Business Daily

From analysis to good news, read the world’s best news in one place